Reviva Pharmaceuticals Holdings (RVPH) AI Stock Analysis

• Market Cap: $33.64M
• Dividend Yield: N/A
• Average Volume (3M): 14.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.12
• Revenue Growth: N/A
• EPS Growth: 58.55%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 115,058,620
• 10 Day Avg. Volume: 22,198,486
• 30 Day Avg. Volume: 14,401,288
• PEG Ratio: 0.04
• Price to Book (P/B): 73.84
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.79
• Enterprise Value/Market Cap: 0.20
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.30
• 1Y Price Target: $5.10
• Price Target Upside: 1600.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.28 ▼(-6.67% Downside)

The score is driven primarily by weak financial fundamentals (no revenue, sizable losses, and ongoing cash burn with reliance on future funding). Technicals also reflect a downtrend with negative momentum. Corporate events add material near-term risk (Nasdaq compliance/delisting pressure and extended regulatory timeline requiring additional financing).

Positive Factors

Low financial leverage

Minimal debt materially lowers financial leverage and bankruptcy risk, giving management structural flexibility to prioritize R&D spending or seek non-debt capital. Over 2–6 months this reduces fixed-cost pressure and preserves optionality for strategic financing or partnerships.

Late-stage CNS candidate (brilaroxazine)

A focused late-stage schizophrenia program represents a durable strategic asset: success could transition Reviva from development to commercial operations and create a sustainable revenue stream. The CNS focus aligns with large, persistent unmet needs and established commercial pathways.

Narrowing losses and improved cash burn

Progressive reduction in operating losses and lower cash burn signal improving cost discipline or program prioritization. If sustained, this trend lengthens runway, lowers near-term financing needs, and improves ability to execute development milestones over coming quarters.

Negative Factors

No revenue and recurring negative cash flow

Absence of product revenue leaves operations fully dependent on financing; persistent negative operating and free cash flow create structural dilution and execution risk. Over months this constrains strategic choices and increases vulnerability to funding market conditions.

Nasdaq bid-price non-compliance and delisting risk

Listing non-compliance introduces a durable governance and liquidity overhang. Potential delisting or forced reverse split can impair trading liquidity, raise cost of capital, damage investor confidence, and materially complicate future equity raises and partnership negotiations.

FDA requests second Phase 3, extending timelines and costs

A regulator-mandated additional pivotal trial materially raises development cost, lengthens time to potential approval, and increases execution risk. Structurally this elevates financing needs and dilution probability and delays any transition to revenue generation for the foreseeable future.

Reviva Pharmaceuticals Holdings Business Overview & Revenue Model

Company Description

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

How the Company Makes Money

Reviva Pharmaceuticals Holdings generates revenue primarily through the development and commercialization of its drug candidates. The company relies on funding from partnerships, collaborations, and potential licensing agreements with larger pharmaceutical companies. These partnerships may include milestone payments and royalties based on the successful development and commercialization of its products. Additionally, Reviva may receive grants or research funding from governmental or non-governmental organizations to support its drug development programs. As a clinical-stage company, its revenue generation is heavily dependent on the successful advancement of its pipeline through clinical trials and achieving regulatory approvals.

Reviva Pharmaceuticals Holdings Financial Statement Overview

Summary

Development-stage profile with no reported revenue and ongoing large losses (TTM EBIT and net loss about -$23M). Cash burn remains substantial (TTM operating/free cash flow about -$27.9M), and equity has been heavily compressed despite minimal debt, increasing reliance on external financing and dilution risk.

Income Statement

RVPH shows no reported revenue across the annual periods and in TTM (Trailing-Twelve-Months), which is common for development-stage biotech but leaves earnings fully dependent on spending levels. Losses remain large (TTM EBIT about -$22.9M; TTM net loss about -$22.8M). There is some improvement versus 2023–2024 (losses narrowed from roughly -$39M in 2023 and about -$30M in 2024), but profitability is still materially negative and visibility is limited without revenue.

Balance Sheet

The balance sheet is helped by very low debt (TTM total debt is $0; 2024 debt was modest at ~$0.46M), reducing financial leverage risk. However, equity has compressed sharply over time (from ~$28.7M in 2021 to ~$0.8M in 2024, then ~$4.5M TTM), reflecting cumulative losses and/or financing impacts. Return on equity is deeply negative (TTM roughly -205%), highlighting that current capital is not generating positive returns and the company may need additional funding to sustain operations.

Cash Flow

Cash generation is weak with consistently negative operating and free cash flow (TTM operating cash flow and free cash flow about -$27.9M; 2024 about -$33.5M). The cash burn improved versus 2024 and 2023, but it remains substantial and recurring. With ongoing negative cash flow and no revenue base shown, the company’s financial flexibility likely depends on external capital raises and careful burn management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	-724.74K
EBITDA	-22.71M	-29.88M	-39.21M	-24.11M	-10.10M	-2.33M
Net Income	-22.76M	-29.92M	-39.26M	-24.34M	-8.52M	-3.78M
Balance Sheet
Total Assets	14.33M	15.50M	23.70M	18.92M	31.40M	8.76M
Cash, Cash Equivalents and Short-Term Investments	13.18M	13.48M	23.37M	18.52M	29.69M	8.76M
Total Debt	0.00	458.15K	0.00	0.00	0.00	0.00
Total Liabilities	9.78M	14.69M	17.98M	10.53M	2.72M	3.30M
Stockholders Equity	4.55M	812.57K	5.72M	8.39M	28.69M	5.47M
Cash Flow
Free Cash Flow	-27.90M	-33.54M	-28.32M	-18.96M	-10.67M	-4.07M
Operating Cash Flow	-27.90M	-33.54M	-28.32M	-18.96M	-10.67M	-4.07M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	35.52M	23.65M	33.17M	7.79M	31.60M	12.83M

Reviva Pharmaceuticals Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVPH, the sentiment is Negative. The current price of 0.3 is below the 20-day moving average (MA) of 0.33, below the 50-day MA of 0.45, and below the 200-day MA of 0.56, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 36.38 is Neutral, neither overbought nor oversold. The STOCH value of 9.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVPH.

Reviva Pharmaceuticals Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRLD	47 Neutral	$104.74M	-1.15	-103.99%	―	250.00%	15.15%
CVM	42 Neutral	$48.77M	-0.75	-176.32%	―	―	48.68%
RVPH	41 Neutral	$33.64M	-0.64	―	―	―	58.55%
PSTV	40 Underperform	$40.69M	-0.12	―	―	-8.16%	22.44%

Reviva Pharmaceuticals Holdings Corporate Events

Reviva Pharmaceuticals Granted Nasdaq Extension to Regain Compliance

Reviva Pharmaceuticals Holdings, which is listed on the Nasdaq Capital Market, has disclosed heightened risks related to maintaining its stock exchange listing after failing to meet Nasdaq’s minimum bid price requirement of $1.00 per share. On May 13, 2025, the company received a non-compliance notice, and after not regaining compliance by the initial November 10, 2025 deadline and being deemed ineligible for a second standard compliance period, it faced a delisting determination on November 11, 2025. A subsequent hearing before a Nasdaq Hearings Panel on January 8, 2026 resulted in an exception allowing Reviva until March 27, 2026 to restore its share price, potentially through measures such as a reverse stock split, though the company warns such an action could hurt share price performance, liquidity, and overall market capitalization. Reviva cautions that failure to regain or maintain compliance could lead to delisting, which in turn could materially reduce stock liquidity and price, impair its ability to raise capital on acceptable terms, and undermine confidence among investors and business partners.

The most recent analyst rating on (RVPH) stock is a Sell with a $0.33 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.

Reviva plans second Phase 3 trial after FDA feedback

At its annual meeting on December 18, 2025, Reviva Pharmaceuticals shareholders elected five directors for one-year terms, ratified Baker Tilly US as the auditor for fiscal 2025, approved executive compensation, and cleared key capital-structure measures, including raising the authorized common shares from 315 million to 515 million and authorizing the board to implement a reverse stock split at a ratio between 1-for-2 and 1-for-20 any time before December 31, 2026; sufficient votes rendered a contingency adjournment proposal unnecessary. On December 23, 2025, the company reported that following a pre-NDA meeting, the FDA recommended a second Phase 3 trial of its schizophrenia candidate brilaroxazine to strengthen efficacy and safety data before a U.S. filing, prompting Reviva to plan the RECOVER-2 registrational study for the first half of 2026, subject to financing, a step that could extend timelines but, if successfully executed, bolster the drug’s regulatory case in a competitive CNS market and underscores the company’s reliance on additional capital to advance late-stage development.

The most recent analyst rating on (RVPH) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.